You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Product menu

VOCABRIA▼(cabotegravir) + REKAMBYS▼(rilpivirine) Phase 3 Trials

The first and only, complete long-acting regimen, offering non-inferior efficacy to daily oral HIV therapy.

VOCABRIA + REKAMBYS is a different way to dose HIV-1 that could offer your patients freedom from daily ARV therapy with dosing once every 2-months during the continuation phase of the treatment.1

In the FLAIR, ATLAS and SOLAR studies, monthly VOCABRIA + REKAMBYS was demonstrated as non-inferior to daily oral therapy. In the: ATLAS-2M study, every 2-month dosing was demonstrated as non-inferior to monthly VOCABRIA + REKMABYS.1-5

These large, global studies included over 2800 subjects.1-6 They were part of a broad clinical programme to show that long-acting therapy is non-inferior to currently available daily HIV treatments.1-6

Vocabria + Rekambys are supported by the following clinical trials, over 48 weeks

NA
Image
image
flair

* HIV-1 RNA <50 copies/mL1

Explore the unmet needs in HIV therapy

PATIENT INTEREST AND NEEDS

Changing the experience of HIV Therapy

Contact us

Request a contact from a GSK/ViiV Representative
References
  1. VOCABRIA Summary of Product Characteristics. ViiV Healthcare; 2024. Available at: https://www.medicines.ie/medicines/vocabria-600-mg-prolonged-release-suspension-for-injection-35220/spc
  2. REKAMBYS Summary of Product Characteristics. ViiV Healthcare 2024. Available at: https://www.medicines.ie/medicines/rekambys-35258/spc#tabs
  3. Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382(12):1112-1123.
  4. Orkin C, Arasteh K, Hernández-Mora MG, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. Published online ahead of print: March 4, 2020. doi:10.1056/NEJMoa1909512.
  5. Overton ET, Richmond G, Rizzardini G, et al. Cabotegravir + rilpivirine every 2 months is noninferior to monthly dosing: Week 48 results from the ATLAS-2M Study. Presented at Conference on Retroviruses and Opportunistic Infections (CROI): March 8-11, 2020; Boston, MA.
  6. Ramgopal MN, Castagna A, Cazanave C, et al. SOLAR 12-Month Results – Randomized Switch Trial of CAB + RPV LA vs. Oral BIC/FTC/TAF. Presented at Conference on Retroviruses and Opportunistic Infections (CROI): February 19–22, 2023. REF-182990.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

REKAMBYS (rilpivirine long acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies.

All other trademarks are owned by the ViiV Healthcare group, or its licensor. 
©2024 GSK group of companies. All rights reserved.

PM-IE-CBR-WCNT-230007
Date of preparation: January 2024